Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
+0.25%
1,104.10
+2.73
+0.25%
—1,101.371,103.631,105.311,091.41——
SIXC
Communications
SIXC
Communications
SIXC
-1.50%
604.16
-9.19
-1.50%
—613.35613.35613.35601.49——
SIXE
Energy
SIXE
Energy
SIXE
-0.09%
1,197.81
-1.02
-0.09%
—1,198.831,199.681,199.751,182.41——
SIXI
Industrials
SIXI
Industrials
SIXI
-0.88%
1,740.41
-15.54
-0.88%
—1,755.951,754.061,756.031,734.69——
SIXM
Financials
SIXM
Financials
SIXM
-0.64%
634.44
-4.07
-0.64%
—638.51637.41637.41633.05——
SIXR
Staples
SIXR
Staples
SIXR
-0.31%
840.90
-2.62
-0.31%
—843.52843.35846.40837.93——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0.38%
215.13
-0.82
-0.38%
—215.95215.95216.84215.06——
SIXT
Technology
SIXT
Technology
SIXT
+2.86%
3,228.71
+89.80
+2.86%
—3,138.913,189.303,230.853,174.76——
SIXU
Utilities
SIXU
Utilities
SIXU
+0.16%
935.87
+1.50
+0.16%
—934.37934.72938.26927.50——
SIXV
Health care
SIXV
Health care
SIXV
-1.37%
1,457.12
-20.31
-1.37%
—1,477.431,474.121,474.121,451.80——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0.83%
2,399.84
+19.65
+0.83%
—2,380.192,389.342,403.042,380.47——
GILD34:BVMF
Gilead Sciences Inc BDR
R$345.70
0.00%
(0.00) 1D
Apr 15, 1:25:50 PM GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for GILD34...
Mkt. cap
161.86B
Avg. vol.
10.00
Volume
0.00
52-wk high
R$394.83
52-wk low
R$268.75
Shares outstanding
1.24B
No. of employees
17K
News stories
From sources across the web
Profile
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. It has recently expanded into different therapeutic areas such as oncology and inflammation. Gilead is a member of the Nasdaq-100 and the S&P 100. Gilead was founded in 1987 under the name Oligogen by Michael L. Riordan. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs like Tamiflu and Vistide that decade. In the 2000s, Gilead received approval for drugs including Viread and Hepsera, among others. It began evolving from a biotechnology company into a pharmaceutical company, acquiring several subsidiaries, though it still relied heavily on contracting to manufacture its drugs. The company continued its growth in the 2010s. Wikipedia
About Gilead Sciences Inc BDR
CEODaniel O'Day
Employees17K
FoundedJun 22, 1987
HeadquartersFoster City, California, United States
SectorBiotechnology
Websitegilead.com
Next call in 12 days
Thu, May 7, 4:30 PM
Fiscal Period
Q1 2026
Normalized EPS / Estimate
-/ (1.91 est.)USD
Revenue / Estimate
-/ (6.92B est.)USD
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earningsInsights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
6.67B
7.08B
7.77B
7.92B
Cost of goods sold
1.54B
1.50B
1.57B
1.62B
Cost of revenue
1.54B
1.50B
1.57B
1.62B
Research and development expenses
1.34B
1.45B
1.33B
1.57B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.22B
1.36B
1.35B
1.78B
Operating expense
2.56B
2.81B
2.69B
3.34B
Total operating expenses
4.10B
4.31B
4.26B
4.96B
Operating income
2.57B
2.77B
3.51B
2.96B
Other non operating income
11.00M
13.00M
-23.00M
51.00M
EBT including unusual items
1.65B
2.43B
3.64B
2.08B
EBT excluding unusual items
2.40B
2.58B
3.34B
2.80B
Income tax expense
334.00M
468.00M
589.00M
-105.00M
Effective tax rate
20.25%
19.28%
16.18%
-5.05%
Other operating expenses
-
-
-
-
Net income
1.32B
1.96B
3.05B
2.18B
Net profit margin
19.72%
27.68%
39.28%
27.55%
Earnings per share
1.81
2.01
2.47
1.86
Interest and investment income
94.00M
73.00M
88.00M
95.00M
Interest expense
-260.00M
-254.00M
-256.00M
-255.00M
Net interest expenses
-166.00M
-181.00M
-168.00M
-160.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
3.26B
3.46B
4.20B
3.65B
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer